N
Naamit Sher
Publications - 12
Citations - 76
Naamit Sher is an academic researcher. The author has contributed to research in topics: Bevacizumab & Combination therapy. The author has an hindex of 4, co-authored 12 publications receiving 67 citations.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study.
Andrew Brenner,Katherine B. Peters,James J. Vredenburgh,Felix Bokstein,Deborah T. Blumenthal,Shlomit Yust-Katz,Idit Peretz,Bernice Oberman,Laurence S. Freedman,Benjamin M. Ellingson,Timothy F. Cloughesy,Naamit Sher,Yael C Cohen,Noa Lowenton-Spier,Tamar Rachmilewitz Minei,Niva Yakov,Itzhak Mendel,Eyal Breitbart,Patrick Y. Wen +18 more
TL;DR: Patients with rGBM who were primed with VB-111 monotherapy that continued after progression with the addition of bevacizumab showed significant survival and PFS advantage, as well as specific imaging characteristics related to Vb-111 mechanism of action.
Patent
Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
TL;DR: In this article, the authors present methods of producing adenoviruses such as pro-and anti-angiogenic vectors and preparations generated thereby, in some embodiments, the viral vectors comprise a heterologous pro- or anti-ANGIogenic gene under the transcriptional control of the murine pre-proendothelin promoter (e.g. PPE-1-3X), for targeted expression of in angiogenic endothelium.
Patent
Methods for use of a specific anti-angiogenic adenoviral agent
TL;DR: In this article, anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera vector.
Patent
Treatment with vb-201
TL;DR: In this paper, unit dosage forms comprising between 1 mg and 100 mg VB-201 and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed, as well as treatment regimens comprising oral administration of Vb-201 once or twice daily for treating an inflammatory disease or disorder.
Patent
Methods of inducing responsiveness to anti-angiogenic agent
TL;DR: In this article, the authors proposed methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter.